P107: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN PATIENTS WITH SICKLE CELL DISEASE

• J Howard,
• K Kuo,
• A Oluyadi,
• H Shao,
• S Morris,
• A Zaidi,
• E Van Beers,
• S Thein

Affiliations

J Howard

1 Department of Hematology, Guy’s and St Thomas’ NHS Foundation Trust, London, UNITED KINGDOM

K Kuo

2 Division of Hematology, University of Toronto, Toronto, ON, CANADA

A Oluyadi

3 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

H Shao

3 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

S Morris

3 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

A Zaidi

3 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

E Van Beers

4 Van Creveldkliniek, Department of Internal Medicine, University Medical Center Utrecht, Utrecht, NETHERLANDS

S Thein

5 Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, UNITED STATES